Treace Medical Concepts, Inc. TMCI R2K
Company Overview
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Why Investors Should Care
Revenue has grown at a 32.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $212.69M (+1.6% YoY); net profit $-59.00M.
- Trailing 12 Months Year-on-year growth — revenue -10.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 32.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 32.44% |
| 1 Year: | -10.20% |
Stock Price Performance
| 1 Year: | -26.54% |
| 6 Months: | +57.14% |
| 3 Months: | +106.57% |
| 1 Month: | +8.37% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross6d ago
- RSI (14)55.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 32.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 42.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TMCI Treace Medical Concepts, Inc. R2K | 4.40 | -4.58 | $285.44M | 0.00% | -33.86% | -66.88% | 32.44% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.26M | 7.74M | 14.27M | 18.71M | 20.65M | 21.62M | 29.05M | 29.97M | 33.05M | 42.20M | 41.95M | 40.76M | 51.11M | 44.45M | 45.09M | 52.57M | 47.39M | 50.21M | 47.20M |
| Gross Profit | 8.87M | 5.65M | 11.36M | 15.38M | 16.71M | 17.37M | 23.92M | 24.68M | 26.96M | 34.16M | 34.28M | 32.76M | 40.98M | 35.67M | 36.13M | 41.89M | 37.75M | 39.71M | 37.41M |
| Operating Income | -1.20M | -1.52M | -63.00K | -1.40M | -4.05M | -5.46M | -8.10M | -11.93M | -11.32M | -13.78M | -13.05M | -17.82M | -18.97M | -21.38M | -15.13M | -15.58M | -16.97M | -15.68M | -17.17M |
| Net Income | -1.61M | -1.97M | -2.65M | -2.43M | -5.08M | -6.42M | -9.04M | -17.23M | -12.13M | -13.45M | -12.27M | -17.52M | -18.68M | -21.21M | -15.36M | -15.92M | -17.40M | -16.29M | -17.96M |
| Diluted EPS | - | - | - | - | -0.10 | -0.12 | -0.16 | -0.31 | -0.22 | -0.23 | -0.20 | -0.28 | -0.30 | -0.34 | -0.25 | -0.25 | -0.28 | -0.26 | -0.28 |
| R&D Expense | 1.43M | 982.00K | 1.51M | 1.87M | 2.42M | 2.54M | 3.05M | 2.98M | 3.80M | 3.41M | 3.53M | 4.35M | 5.26M | 5.16M | 4.96M | 5.56M | 5.50M | 4.68M | 4.62M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 39.42M | 57.37M | 94.42M | 141.84M | 187.12M | 209.36M | 212.69M |
| Gross Profit | 31.79M | 44.90M | 77.53M | 116.31M | 151.94M | 168.26M | 169.75M |
| Operating Income | -3.54M | 855.00K | -16.51M | -34.84M | -51.43M | -55.69M | -54.15M |
| Net Income | -4.26M | -3.67M | -20.55M | -42.81M | -49.53M | -55.74M | -59.00M |
| Diluted EPS | - | -0.12 | -0.43 | -0.77 | -0.81 | -0.90 | -0.93 |
| R&D Expense | 5.07M | 5.85M | 10.20M | 13.58M | 15.44M | 20.59M | 20.28M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 41.81M | 140.82M | 159.02M | 251.91M | 217.09M | 190.58M |
| Total Equity | 5.95M | 3.16M | 776.00K | 93.07M | 60.53M | 137.94M | 112.89M | 87.33M |
| Cash & Equivalents | 1.28M | 12.14M | 18.08M | 105.83M | 19.47M | 12.98M | 11.35M | 10.71M |
| Long Term Debt | - | - | 29.19M | 29.36M | 52.71M | 53.01M | 53.31M | 55.58M |
| Total Liabilities | - | - | 41.03M | 47.75M | 98.50M | 113.97M | 104.20M | 103.25M |
| Current Liabilities | - | - | 11.60M | 18.21M | 30.25M | 45.03M | 34.92M | 30.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.67M | -4.49M | - | -30.65M | -34.58M | -37.17M | -15.97M |
| Investing Cash Flow | -1.21M | -1.07M | - | -76.52M | -81.30M | 35.38M | 13.25M |
| Financing Cash Flow | 19.74M | 11.50M | - | 20.81M | 109.38M | 160.00K | 2.08M |
| Capital Expenditure | -1.21M | -1.07M | - | -14.84M | -11.46M | -11.59M | -13.52M |
| Free Cash Flow | -8.88M | -5.56M | - | -45.49M | -46.03M | -48.76M | -29.49M |
| Net Change in Cash | - | - | - | -86.36M | -6.49M | -1.63M | -642.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 80.6% | 78.3% | 82.1% | 82.0% | 81.2% | 80.4% | 79.8% |
| Operating Margin % | -9.0% | 1.5% | -17.5% | -24.6% | -27.5% | -26.6% | -25.5% |
| Net Margin % | -10.8% | -6.4% | -21.8% | -30.2% | -26.5% | -26.6% | -27.7% |
| ROE % | -134.9% | -472.7% | -22.1% | -70.7% | -35.9% | -49.4% | -67.6% |
| ROCE % | - | 2.8% | -13.5% | -27.1% | -24.9% | -30.6% | -33.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 9.81% | 6.36M | $28.51M |
| 2 | Gagnon Securities, LLC | 8.02% | 5.20M | $23.30M |
| 3 | Blackrock Inc. | 5.15% | 3.34M | $14.96M |
| 4 | Bank of America Corporation | 4.95% | 3.21M | $14.40M |
| 5 | Vanguard Capital Management LLC | 2.25% | 1.46M | $6.55M |
| 6 | State Street Corporation | 1.90% | 1.24M | $5.54M |
| 7 | CIBC Bancorp USA Inc. | 1.88% | 1.22M | $5.46M |
| 8 | Millennium Management Llc | 1.77% | 1.15M | $5.14M |
| 9 | AQR Capital Management, LLC | 1.64% | 1.06M | $4.76M |
| 10 | Geode Capital Management, LLC | 1.56% | 1.01M | $4.53M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TMCI
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Short Interest Down 46.6% in June - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPRVJWaUZ1TVVPUmtzWFRqLWVxS0Q0TUJhc25hQ25RUC1vZ1NJNkFEb2dzcWVLMjhjNlZsTWpVZW51UTdXU05ic2xzT1VkMnRZTE41YmlrclRWYVRNSkhkb3lZZWxMc204Y3haMHVlZnQzcll6Ri1jZ2Fmb0xDNEdJTGJ1SHk0N3M4TTNDdk…
$TMCI stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPMzNNVmlnRm91RU1DSGhnZFNsU1dERzdZZlNIYWsyWF9hS25XRVZwNFprUGRKNzV0bGwwR0pzTG05ODRDRWRIVU1TX1VwZXI4aEJhZklESy1OcmRmRmdBZ3FjVDRkd0JuV3RsMkVidTBlNVUzZEFZWWhQTXJIeVluX2lhek9SUklmNFJMUF…
How The Treace Medical Concepts (TMCI) Story Is Shifting With Mixed Analyst Expectations - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPVm5rWW1DUnRaQ1I1NmFQYjZfN3poZzg4WGkxaU1Ub0pPeTZUVkVlb0RaZDU5TG1rVnZpMWxCalpmYVhOdnBMQWpEaWY3dHF1QmgzOTVFNG0yOE43WTNMQk9PYkhOVjBXRHZlRGxzeTRRRFFLc0hreThrVHpzVm1xX19qLU5qZWc4Q3JHUH…
Treace Medical (NASDAQ: TMCI) CEO adds 52,317 shares in open-market purchases - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOTy01bFZ2eHNfMlMyWG5vZVgtSTliUjgyT2RFbXJqYWl6OTE5Vlo3QkZUU2FJRlRidXZGSS1lOU1IMTJkZHJKY3JVd0JOVzhHcXpKVE1EWlVXSzNsLWNVVmJIcmE0bFN0M1RlX1Z0bkljM1pvWVRkTVcxR0w2MEJ0Z3JMTGtmN2ZwY25aV2…
(TMCI) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOMHJCcmIzM0pnRGhRYmpCeDhpTWNlTW95cGRIdXhxRHBENEwwMTllN1hEYTRkOFJEVUNTY0FpNHM1SVd4Rll5Y01EQkRXN29PWDhVMXlldVRzYWZlY25zVmQ2dEwxcTY0M0xpV0ZQSGIxZ3ZNSnVGeHdoUEFxVE02TVU1YTFCS1pGR1Z6Vz…
Treace Medical Concepts CEO John T. Treace buys $210,967 in stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNYVNOUkI4YlNsZUVmMjNJU0hJMGk4V2o3X2FEREM4V085aWFzNS1IelphLVNJNW1ibXBTQzZGbjNwa1haQkxVUEZ1LW5ETW0tcnY1Y2lTOV9zRWZSMnpVT1hucTVweDZrdk1uZzdSUjFOYXBaTE5CUWs0TzdIS0xlQ1huSnlGZExpMm9NUG…
TMCI — Frequently Asked Questions
What is the current share price of Treace Medical Concepts, Inc. (TMCI)?
As of 2026-07-15 16:51 PDT, Treace Medical Concepts, Inc. (TMCI) trades at $4.40 on NasdaqGS. Its 52-week range is $1.20 to $7.70.
What is the market capitalisation of TMCI?
Treace Medical Concepts, Inc. (TMCI) has a market capitalisation of $285.44M on NasdaqGS.
What is the P/E ratio of TMCI?
TMCI trades at a trailing price-to-earnings (P/E) ratio of -4.58. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 3.76.
What is the return on equity (ROE) of TMCI?
TMCI has a return on equity (ROE) of -66.88%. Its return on capital employed (ROCE) is -33.86%.
Is TMCI a good stock to buy?
This page provides a data-driven analysis of Treace Medical Concepts, Inc. (TMCI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.